Clinical Trial: Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

U.S., Oct. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07851025) titled 'Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer' on Sept. 15.

Brief Summary: This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recombination Deficient (HRD) negative advanced ovarian cancer.

Study Start Date: Sept. 16

Study Type: INTERVENTIONAL

Condition: Epithelial Ovarian Cancer

Intervention: DRUG: Torvutatug samrotecan

Antibody drug conjug...